The article reviews the emerging role of immunogenic cell death (ICD) in cancer immunotherapy. ICD is a form of regulated cell death that enhances tumor immunogenicity and activates innate and adaptive immune responses. The review highlights the historical and recent discoveries related to ICD modes and their mechanisms, particularly in the context of cancer immunotherapy. Key findings include the induction of ICD by atypical interferon (IFN)-stimulated genes (ISGs), such as polo-like kinase 2 (PLK2), during hyperactive type I IFN signaling. The therapeutic potential of ICD is discussed, emphasizing its relevance in both preclinical and clinical settings. The review also explores various other cell death modes, such as necroptosis, ferroptosis, pyroptosis, and disulfidoptosis, and their potential as ICD-like forms. The authors highlight the importance of understanding the mechanisms by which different cell death modes enable protective anti-tumor immunity and the development of reagents for tumor-specific ICD induction. The article concludes by discussing the challenges and future directions in ICD-mediated cancer immunotherapy.The article reviews the emerging role of immunogenic cell death (ICD) in cancer immunotherapy. ICD is a form of regulated cell death that enhances tumor immunogenicity and activates innate and adaptive immune responses. The review highlights the historical and recent discoveries related to ICD modes and their mechanisms, particularly in the context of cancer immunotherapy. Key findings include the induction of ICD by atypical interferon (IFN)-stimulated genes (ISGs), such as polo-like kinase 2 (PLK2), during hyperactive type I IFN signaling. The therapeutic potential of ICD is discussed, emphasizing its relevance in both preclinical and clinical settings. The review also explores various other cell death modes, such as necroptosis, ferroptosis, pyroptosis, and disulfidoptosis, and their potential as ICD-like forms. The authors highlight the importance of understanding the mechanisms by which different cell death modes enable protective anti-tumor immunity and the development of reagents for tumor-specific ICD induction. The article concludes by discussing the challenges and future directions in ICD-mediated cancer immunotherapy.